Clinical trial
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's…
NCT00430521 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00430521 |
|---|---|
| Title | Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) |
| Official title | Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza, Influenza Vaccines |
| Intervention type | Biological |
| Interventions | Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2 |
| Enrollment | 512 |
| Start date | Feb 5, 2007 |
| Primary completion | Oct 20, 2008 |
| Completion | Oct 20, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Oct 28, 2019 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: